Preclinical biochemical studies indicated that rivastigmine has central nervous system selectivity over peripheral inhibition. It ameliorated memory impairment in rats with forebrain lesions. Its elimination half-life is less than 2 hours, and it is converted to an inactive metabolite at the site of action, bypassing hepatic metabolic pathways. Its disposition essentially is unaltered in patients with renal or hepatic impairment. It also has dose-dependent effects on AChE inhibition.
Gastrointestinal symptoms are the most frequently reported adverse events.
They occurred mostly during the dosage titration phase and decreased during the maintenance phase. Rivastigmine offers clinicians another therapeutic agent to treat Alzheimer's disease. HIV-Associated Lipodystrophy Syndrome Roula B. Qaqish, Pharm. D., Evelyn Fisher, M.D., John Rublein, Pharm. These metabolic and physical changes are called the HIV-associated lipodystrophy syndrome.